awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q51007218-4ED65FF7-1D3E-4E54-B588-ED7BF076C2FE
Q51007218-4ED65FF7-1D3E-4E54-B588-ED7BF076C2FE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51007218-4ED65FF7-1D3E-4E54-B588-ED7BF076C2FE
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
P2860
Q51007218-4ED65FF7-1D3E-4E54-B588-ED7BF076C2FE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51007218-4ED65FF7-1D3E-4E54-B588-ED7BF076C2FE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5d9d46e1d54d3b0431a8df4bf7ab6b928e41807e
P2860
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.